Synergistic induction of apoptosis by sulindac and simvastatin in A549 human lung cancer cells via reactive oxygen species-dependent mitochondrial dysfunction

International Journal of Oncology

Volumn 43, Issue 1, 2013, Pages 262-270

  Hwang, Ki Eun ^a   Park, Chul ^a   Kwon, Su Jin ^a   Kim, Young Suk ^a   Park, Do Sim ^a   Lee, Mi Kyung ^b   Kim, Byoung Ryun ^b   Park, Seong Hoon ^b   Yoon, Kwon Ha ^b   Jeong, Eun Taik ^a   Kim, Hak Ryul ^a  

^a Wonkwang University School of Medicine   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

A549 cells; Apoptosis; Reactive oxygen species; Simvastatin; Sulindac

Indexed keywords

CASPASE; CYTOCHROME C; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; SULINDAC;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELLULAR PARAMETERS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOSOLIC RELEASE; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL TRANSMEMBRANE POTENTIAL; PRIORITY JOURNAL; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; MITOCHONDRIA; REACTIVE OXYGEN SPECIES; SIMVASTATIN; SULINDAC;

EID: 84879633429     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1933     Document Type: Article

References (43)

1. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M and Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127-134, 2000. (Pubitemid 30064984)
2. Velmurugan B, Mani A and Nagini S: Combination of S-allylcysteine and lycopene induces apoptosis by modulating Bcl-2, Bax, Bim and caspases during experimental gastric carcinosenesis. Eur J Cancer Prev 14: 387-393, 2005. (Pubitemid 41104948)
3. Lin J, Hsiao PW, Chiu TH and Chao JI: Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol 70: 658-667, 2005. (Pubitemid 41058700)
4. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J and Sarkar FH: Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65: 9064-9072, 2005. (Pubitemid 41377399)
5. Khor TO, Keum YS, Lin W, Kim JH, Hu R, Shen G, Xu C, Gopalakrishnan A, Reddy B, Zheng X, Conney AH and Kong AN: Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res 66: 613-621, 2006. (Pubitemid 43165919)
6. Giardiello FM, Spannhake EW, DuBois RN, Hylind LM, Robinson CR, Hubbard WC, Hamilton SR and Yang VW: Prostaglandin levels in human colorectal mucosa: effects sulindac in patients with familial adenomatous polyposis. Dig Dis Sci 43: 311-316, 1998. (Pubitemid 28124605)
7. Shiff SJ, Qiao L, Tsai LL and Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96: 491-503, 1995.
8. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanism underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998. (Pubitemid 28083803)
9. Williams CS, Mann M and DuBios RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916, 1999. (Pubitemid 30066236)
10. Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R and Ahnen DJ: Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 57: 267-271, 1997. (Pubitemid 27036604)
11. Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS and Pamukcu R: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55: 3110-3116, 1995.
12. Tegeder I, Pfeilschifter J and Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15: 2057-2072, 2001. (Pubitemid 32927924)
13. Seo SK, Lee HC, Woo SH, Jin HO, Yoo DH, Lee SJ, An S, Choe TB, Park MJ, Hong SI, Park IC and Rhee CH: Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis 12: 195-209, 2007. (Pubitemid 46009513)
14. Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
15. Chan KK, Oza AM and Siu LL: The statins as anticancer agents. Clin Cancer Res 9: 10-19, 2003. (Pubitemid 36109711)
16. Demierre MF, Higgins PD, Gruber SB, Hawk E and Lippman SM: Statins and cancer prevention. Nat Rev Cancer 5: 930-942, 2005. (Pubitemid 41766782)
17. Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA and Dimitroulakos J: Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 11: 2398-2407, 2005. (Pubitemid 40490201)
18. Wong WW, Dimitroulakos J, Minden MD and Penn LZ: HMB-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16: 508-519, 2002. (Pubitemid 34460459)
19. Holstein SA and Hohl RJ: Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 1: 141-149, 2001.
20. Feleszko W, Mlynarczuk I, Olszewska D, Jalili A, Grzela T, Lasek W, Hoser G, Korczak-Kowalska G and Jakobisiak M: Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer 100: 111-118, 2002. (Pubitemid 34602074)
21. Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ and Arcaro A: Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signaling. Oncogene 25: 877-887, 2006. (Pubitemid 43237706)
22. Kozar K, Kaminski R, Legat M, Kopec M, Nowis D, Skierski JS, Koronkiewicz M, Jakobisiak M and Golab J: Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol 24: 1149-1157, 2004.
23. Wallace JL: Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 112: 1000-1016, 1997.
24. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn R, Anderson WF, Zauber A, Hawk E and Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Eng J Med 352: 1071-1080, 2005.
25. Psaty BM and Potter JD: Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med 355: 950-952, 2006. (Pubitemid 44315987)
26. Jalving M, Koorntra JJ, De Jong S, De Vries EG and Kleibeuker JH: Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment Pharmacol Ther 21: 321-339, 2005. (Pubitemid 40313936)
27. Xiao H and Yang CS: Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int J Cancer 123: 983-990, 2008.
28. Suh N, Reddy BS, DeCastro A, Paul S, Lee HJ, Smolarek AK, So JY, Simi B, Wang CX, Janakiram NB, Steele V and Rao CV: Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats. Cancer Prev Res (Phila) 4: 1895-1902, 2011.
29. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
30. Wolf CM and Eastman A: The temporal relationship between protein phosphatase, mitochondrial cytochrome c release. Exp Cell Res 247: 505-513, 1999. (Pubitemid 29394788)
31. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, Steele GD Jr and Chen LB: Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 88: 3671-3675, 1991. (Pubitemid 21916685)
32. Park JH, Kim EJ, Jang HY, Shim H, Lee KK, Jo HJ, Kim HJ, Yang SH, Jeong ET and Kim HR: Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep 20: 379-384, 2008.
33. Ralph SJ, Rondriguez-Enriquez S, Neuzil J, Saavedra E and Moreno-Sanchez R: The causes of cancer revisited: 'mitochondrial malignancy' and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med 31: 145-170, 2010.
34. Copeland WC, Wachsman JT, Johnson FM and Penta JS: Mitochondrial DNA alterations in cancer. Cancer Invest 20: 557-569, 2002. (Pubitemid 34686350)
35. Seo SK, Lee HC, Woo SH, Jin HO, Yoo DH, Lee SJ, An S, Choe TB, Park MJ, Hong SI, Park IC and Rhee CH: Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis 12: 195-209, 2007. (Pubitemid 46009513)
36. Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, Smith CL and Youle RJ: The role of dynamic-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell 1: 515-525, 2001. (Pubitemid 33586103)
37. Karbowski M, Lee YJ, Gaume B, Jeong SY, Frank S, Nechushtan A, Santel A, Fuller M, Smith CL and Youle RJ: Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J Cell Biol 159: 931-938, 2002. (Pubitemid 36055748)
38. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998. (Pubitemid 28406816)
39. Li LY, Luo X and Wang X: Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412: 95-99, 2001. (Pubitemid 32851517)
40. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA and Davis RJ: Requrement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288: 870-874, 2000. (Pubitemid 30257738)
41. Burdon RH: Control of cell proliferation by reactive oxygen species. Biochem Soc Trans 24: 1028-1032, 1996.
42. Minami T, Adachi M, Kawamura R, Zhang Y, Shinomura Y and Imai K: Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin Cancer Res 11: 5248-5256, 2005. (Pubitemid 41003713)
43. Fiers W, Beyaert R, Declercq W and Van den Abeele P: More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 18: 7719-7730, 1999. (Pubitemid 30052757) Welfare